NCT03546881 (SOFtPERIPHERAL) is a NA clinical trial of fusion imaging guidance technology in Arteriopathy, sponsored by Nantes University Hospital.

Who is sponsoring NCT03546881?

NCT03546881 is sponsored by Nantes University Hospital.

What drugs are being tested in NCT03546881?

Interventions in NCT03546881: fusion imaging guidance technology, 2D X-ray screen.

What condition does NCT03546881 study?

NCT03546881 studies Arteriopathy.

Is NCT03546881 still recruiting?

NCT03546881 is currently terminated. Last updated 23 May 2023.

Last reviewed 2023-05-23 · How we verify

NCT03546881: SOFtPERIPHERAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety of Fusion Guidance During Peripheral Revascularisation

Terminated NA Last updated 23 May 2023

What this trial tests

NA trial testing fusion imaging guidance technology in Arteriopathy in 77 participants. Terminated before completion.

Timeline

18 June 2018

Primary endpoint
16 October 2019

16 October 2019

Quick facts

Lead sponsor	Nantes University Hospital
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	77
Start date	18 June 2018
Primary completion	16 October 2019
Estimated completion	16 October 2019
Sites	1 location across France

Drugs / interventions tested

fusion imaging guidance technology
2D X-ray screen

Conditions studied

Arteriopathy — all drugs for Arteriopathy →

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Arteriopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study the Patient and staff Safety regarding the radiation exposure during the procedure with and without the fusion imaging guidance technology in treatment of peripheral artery disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Nantes University Hospital trials

Trials by the same sponsor.

NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03546881 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
Last refreshed: 23 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03546881.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing